Development of a high throughput screening Galanin 3 receptor assay |
R21 |
Steven J. Brown, Scripps |
A cell-based screen for inhibitors of intracellular Abeta aggregation |
R21 |
Matthew P. Delisa, Cornell |
Chemical probes for uncovering differential regulators of apoptosis in cells |
R03 |
Monanish Deshmukh, UNC |
HTS technology for discovery of drugs targeting GPCR oligomers |
R21 |
Pyare L. Khanna, DiscoveRx Corporation |
A cell-based screen for small molecule binders of mutant huntingtin messenger RNA |
R21 |
Robert E. Hughes, Buck Institute for Age Research |
Inhibitor screens for five MAPK kinase kinases important in human disease |
R21 |
Gary L. Johnson, UNC |
Assay development to identifiy palmitoylation inhibitors of neuronal proteins |
R21 |
Maurine E. Linder, Washington U |
Multiplexed flow cytometry screens for RGS inhibitors |
R21 |
Richard R. Neubig, University of Michigan |
High-throughput screening assay development for axonopathic neurodegeration |
R21 |
Norbert Perrimon, Harvard |
Assay development relating to the HTS of the neuropeptide Y-Y2 receptor |
R21 |
Claes Wahlestedt, Scripps |
Discovery of novel allosteric modulators of the M1 muscarinic receptor |
XO1 |
P. Jeffrey Conn, Vanderbilt |
Ligands for premortem diagnosis and treatment of Alzheimer’s disease |
XO1 |
Jeff A. Kuret, Ohio State |
Discovery of novel allosteric agonist of the M4 muscarinic receptor |
XO1 |
Colleen M. Niswender, Vanderbilt |
EphA4 receptor antagonists for nervous system repair |
XO1 |
Elena B. Pasquale, Burnham Institute |
Allosteric modulators of D1 receptors |
XO1 |
Val J. Watts, Purdue |